Lost Password? No account yet? Register

Advertisement

New Media Advertisement
Cyntellect enters research collaboration with Burnham Institute PDF Print E-mail
User Rating: / 0
PoorBest 

Cyntellect, a privately-held biotechnology company, and the Burnham Institute for Medical Research (Burnham) have entered into a joint collaboration to develop new applications on Cyntellect's in situ live cell imaging and laser processing product (called LEAP) to accelerate research by Burnham's scientists.

Cyntellect is a life sciences company committed to revolutionizing the use of living cells in life science research and cellular therapy. The collaboration efforts will focus on developing applications of LEAP for automated purification of stem cells, stem cell colonies and the differentiated cells derived from stem cells.

Cyntellect and Burnham expect these new applications will accelerate discovery of new knowledge of stem cell differentiation factors and pathways, as well as generate cell populations that may be used to deliver the potential therapeutic benefits of stem cells.

Under the agreement, Burnham will gain access to LEAP and Cyntellect will gain certain commercial rights to discoveries under the collaboration. "In situ laser processing with LEAP has provided us the unique ability to purify rare adherent cell types in an efficient, automated and sterile manner," said Professor Mark Mercola associate director, Del E. Webb Neuroscience, Aging and Stem Cell Research Center. "We also believe LEAP can be a transforming technology in the downstream use of stem cells and their progeny as it has clear potential as a sample preparation system for adherent cell types derived from stem cell populations."

LEAP is an automated live cell analysis and processing system that combines high-speed optical imaging (brightfield or fluorescence) and real-time image analysis with high-speed in situ laser manipulation of cells.

"Burnham scientists are clearly among the elite in the world of stem cell biology and we are excited to be working closely with them to exploit LEAP's capabilities to improve their potential in working with stem cells," stated Dr Fred Koller, Cyntellect's president and CEO. "It is an important and noble endeavor that we hope and expect will offer some novel and powerful solutions to the life science and therapeutic markets."

Burnham Institute for Medical Research is dedicated to revealing the fundamental molecular causes of disease and devising the innovative therapies of tomorrow.

 
Next >

Retailing

Kmart Pharmacy has launch of the American Fare Dollar Program, which offers pharmacy customers a choice of 10 over-the-counter (OTC) medications from Kmart's proprietary American Fare brand for only…     Readmore

Image

Outsourcing

The pharmaceutical manufacturers in the United States have attacked the proposed pharma policy of India saying that it would contravene the stated goal of liberalizing the sector, and sought some…     Readmore

Image

Homeopathy

The Homeopatic manufacturing units must fulfill the conditions stated by the government of India under 67-G     Readmore

FDA

Invitrogen Corporation, a provider of essential life science technologies for research, production and diagnostics,  has received U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its SPOT-Light(R) HER2…     Readmore

Biotechnology

Attractive incentives and tax soaps offered by the Malaysian government for the biotech and research based companies is luring some major Indian pharmaceutical players to set up units in…     Readmore

Nanotechnology

The UK Royal Commission has issued a report on the spread of nanomaterials, stating that “urgent action [is] needed on testing and regulation”. In its report the Commission found…     Readmore

Packaging

Bilcare Research has launched a product to help check the menace of counterfeit drugs. The product has a label with a unique bar code made out of nanotechnology and…     Readmore